Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.

Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R.

Cell. 2012 Dec 7;151(6):1185-99. doi: 10.1016/j.cell.2012.10.047.

2.

USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation.

Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q, Kong S, Ye J, Gao B, Fang D.

Cell Rep. 2013 Dec 26;5(6):1639-49. doi: 10.1016/j.celrep.2013.11.029. Epub 2013 Dec 12.

3.

E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells.

Wu M, Seto E, Zhang J.

Oncotarget. 2015 May 10;6(13):11252-63.

4.

SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.

Jeong SM, Lee A, Lee J, Haigis MC.

J Biol Chem. 2014 Feb 14;289(7):4135-44. doi: 10.1074/jbc.M113.525949. Epub 2013 Dec 24.

5.

The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma.

Chen X, Hao B, Liu Y, Dai D, Han G, Li Y, Wu X, Zhou X, Yue Z, Wang L, Cao Y, Liu J.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):364-9. doi: 10.1016/j.bbrc.2014.02.116. Epub 2014 Mar 4.

PMID:
24607900
6.

The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells.

Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A.

J Cell Biochem. 2015 Oct;116(10):2210-26. doi: 10.1002/jcb.25171.

PMID:
25808624
7.

The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.

Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R.

Cell. 2010 Jan 22;140(2):280-93. doi: 10.1016/j.cell.2009.12.041.

8.

SIRT6: a master epigenetic gatekeeper of glucose metabolism.

Zhong L, Mostoslavsky R.

Transcription. 2010 Jul-Aug;1(1):17-21. doi: 10.4161/trns.1.1.12143.

9.

Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion.

Zhang P, Tu B, Wang H, Cao Z, Tang M, Zhang C, Gu B, Li Z, Wang L, Yang Y, Zhao Y, Wang H, Luo J, Deng CX, Gao B, Roeder RG, Zhu WG.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10684-9. doi: 10.1073/pnas.1411026111. Epub 2014 Jul 9.

10.

Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder.

Wu M, Dickinson SI, Wang X, Zhang J.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6504-13. eCollection 2014.

11.

Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming.

Zwaans BM, Lombard DB.

Dis Model Mech. 2014 Sep;7(9):1023-32. doi: 10.1242/dmm.016287. Epub 2014 Aug 1. Review.

12.

The histone deacetylase SIRT6: at the crossroads between epigenetics, metabolism and disease.

Etchegaray JP, Zhong L, Mostoslavsky R.

Curr Top Med Chem. 2013;13(23):2991-3000. Review.

PMID:
24171769
13.

Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context.

Dean JL, McClendon AK, Stengel KR, Knudsen ES.

Oncogene. 2010 Jan 7;29(1):68-80. doi: 10.1038/onc.2009.313. Epub 2009 Oct 5.

PMID:
19802012
14.

Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer.

Kugel S, Feldman JL, Klein MA, Silberman DM, Sebastián C, Mermel C, Dobersch S, Clark AR, Getz G, Denu JM, Mostoslavsky R.

Cell Rep. 2015 Oct 20;13(3):479-88. doi: 10.1016/j.celrep.2015.09.022. Epub 2015 Oct 8.

15.

Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis.

Kim HS, Xiao C, Wang RH, Lahusen T, Xu X, Vassilopoulos A, Vazquez-Ortiz G, Jeong WI, Park O, Ki SH, Gao B, Deng CX.

Cell Metab. 2010 Sep 8;12(3):224-36. doi: 10.1016/j.cmet.2010.06.009.

16.

Targeting aberrant cancer metabolism - The role of sirtuins.

Kleszcz R, Paluszczak J, Baer-Dubowska W.

Pharmacol Rep. 2015 Dec;67(6):1068-80. doi: 10.1016/j.pharep.2015.03.021. Epub 2015 Apr 17. Review.

PMID:
26481524
17.

SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.

Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong S, Koo CY, Harada-Shoji N, Tsang JW, Coombes RC, Schwer B, Khoo US, Lam EW.

Carcinogenesis. 2013 Jul;34(7):1476-86. doi: 10.1093/carcin/bgt098. Epub 2013 Mar 20.

18.

Sirt6 regulates postnatal growth plate differentiation and proliferation via Ihh signaling.

Piao J, Tsuji K, Ochi H, Iwata M, Koga D, Okawa A, Morita S, Takeda S, Asou Y.

Sci Rep. 2013 Oct 23;3:3022. doi: 10.1038/srep03022.

19.

The Warburg effect in 2012.

Bayley JP, Devilee P.

Curr Opin Oncol. 2012 Jan;24(1):62-7. doi: 10.1097/CCO.0b013e32834deb9e. Review.

PMID:
22123234
20.

SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer.

Ming M, Han W, Zhao B, Sundaresan NR, Deng CX, Gupta MP, He YY.

Cancer Res. 2014 Oct 15;74(20):5925-33. doi: 10.1158/0008-5472.CAN-14-1308.

Items per page

Supplemental Content

Write to the Help Desk